PATENT CLAIM ANALYSIS

Application Number: 15910322
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "04400A"]

Abstract:
A composition is provided that comprises a therapeutic agent encapsulated by a milk-derived microvesicle. The compositions can include therapeutic agents such as phytochemical agents or chemotherapeutic agents, while the milk-derived microvesicle can be derived from raw milk or colostrum. Further provided are methods for isolating a microvesicle that includes the steps of obtaining an amount of milk, and subjecting the milk to a series of sequential centrifugations configured to yield greater than about 300 mg of microvesicle protein per 100 ml of milk. Methods of modifying an immune response and treating a cancer in which a milk-derived microvesicle composition is administered are also provided.

Claim (Index 28):
A composition, comprising a therapeutic agent encapsulated by a milk-derived microvesicle, wherein the milk-derived microvesicle is isolated by obtaining an amount of milk and subjecting the milk to a series of sequential centrifugations such that a yield greater than about 50 mg of microvesicle protein per 100 ml of milk is recovered, and then loading the therapeutic agent on the microvesicle by suspending therapeutic agents in PEG-400 and then mixing the PEG-400-suspended therapeutic agents in with the milk-derived exosomes and then treating the mixture with low-speed centrifugation or by dissolving the therapeutic agents in ethanol and mixing with the milk-derived exosomes and then subjecting the mixture to low-speed centrifugation for a predetermined period of time followed by subjecting the mixture to high-speed centrifugation or by mixing the therapeutic agents in ethanol with 100,000 whey and then subjecting the mixture to low-speed centrifugation for a predetermined period of time followed by subjecting the mixture to 120,000\u00d7g centrifugation for a predetermined period of time, wherein the therapeutic agent is a chemotherapeutic agent selected from doxorubicin, paclitaxel, docetaxel, and combinations thereof.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 90.0
- Lexical Diversity: 1.5493
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14770634', '14825957', '14438172', '15458552', '15257669']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.744651115539899
- 35 USC 102 Novelty (BERT): 0.7126281362078207
- Combined Prediction Score: 0.7414488176066911
- Mean Citation Score: 393.542248
- Max Citation Score: 777.15063
- Similarity Product: 748.9143971186203

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test